News & Updates

The investigational drug ABX464, also known as obefazimod, helps reduce disease activity in patients with rheumatoid arthritis (RA), according to the results of a phase II trial. The 50-mg dose is well tolerated, while the higher dose is associated with mild-to-moderate adverse effects resulting in treatment discontinuation.

Treatment with BI 1015550, a novel investigational phosphodiesterase 4 (PDE4) inhibitor, slows lung function decline in patients with idiopathic pulmonary fibrosis (IPF) with or without background antifibrotic therapy, according to a 12-week phase II trial data presented at ATS 2022.

Pregnancies in women with rheumatic and systemic autoimmune diseases—including systemic lupus erythematosus, spondyloarthritis, and rheumatoid arthritis—pose significant health risks and are likely to lead to unfavourable outcomes, according to several studies presented at this year’s European Alliance of Associations for Rheumatology (EULAR) Congress.

The risks of cardiovascular disease (CVD) and end-stage kidney disease (ESKD) are elevated twofold in individuals with youth-onset type 2 diabetes (T2D), which is partly caused by the greater burden of obesity and other metabolic risk factors in this population, relative to those with type 1 diabetes (T1D), according to a Hong Kong study.

An android fat deposition pattern, independent of body mass index (BMI), appears to predict higher odds of nonalcoholic fatty liver disease (NAFLD) in both men and women, but its effect on fibrosis is only seen in females, suggests a US study.

A new study presented at the recent 2022 Scientific Sessions of the American Diabetes Association (ADA 2022) has identified a novel genetic locus associated with heart failure (HF) risk among patients with type 2 diabetes (T2D). This locus appears to play a role in the metabolism of valine, a branched chain amino acid.